Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations
Authors:
- Constance PetiteauCPConstance Petiteau
- Gwladys Robinet-ZimmermannGRGwladys Robinet-Zimmermann
- Adèle RiotARAdèle Riot
- Marine DorbeauMDMarine Dorbeau
- Nicolas RichardNRNicolas Richard
- Cécile Blanc-FournierCBCécile Blanc-Fournier
- Frédéric BibeauFBFrédéric Bibeau
- Simon DeshayesSDSimon Deshayes
- Emmanuel BergotEBEmmanuel Bergot
- Radj GervaisRGRadj Gervais
- Guénaëlle LevalletGLGuénaëlle Levallet
Open Access
- 3 November 2021
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 28 (6) , 4432-4445
Abstract
Epidermal growth factor receptor (EGFR) genotyping, a critical examen for the treatment decisions of patients with non-small cell lung cancer (NSCLC), is commonly assayed by next-generation sequencing (NGS), but this global approach takes time. To determine whether rapid EGFR genotyping tests by the IdyllaTM system guides earlier therapy decisions, EGFR mutations were assayed by both the IdyllaTM system and NGS in 223 patients with NSCLC in a bicentric prospective study. IdyllaTM demonstrated agreement with the NGS method in 187/194 cases (96.4%) and recovered 20 of the 26 (77%) EGFR mutations detected using NGS. Regarding the seven missed EGFR mutations, five were not detected by the IdyllaTM system, one was assayed in a sample with insufficient tumoral cells, and the last was in a sample not validated by the IdyllaTM system (a bone metastasis). IdyllaTM did not detect any false positives. The average time between EGFR genotyping results from IdyllaTM and the NGS method was 9.2 ± 2.2 working days (wd) (12.6 ± 4.0 calendar days (cd)). Subsequently, based on the IdyllaTM method, the timeframe from tumor sampling to the initiation of EGFR-TKI was 7.7 ± 1.2 wd (11.4 ± 3.1 cd), while it was 20.3 ± 6.7 wd (27.2 ± 8.3 cd) with the NGS method (p < 0.001). We thus demonstrated here that the IdyllaTM system contributes to improving the therapeutic care of patients with NSCLC by the early screening of EGFR mutations.Keywords
Funding Information
- AstraZeneca (France) (2018-015083-EC)
- Caen University Hospital (INNOV_Eclair)
This publication has 45 references indexed in Scilit:
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancerOncotarget, 2017
- Financial implications of Idylla testing in colorectal cancer, lung cancer and melanoma: a French laboratory point of viewJournal of Clinical Pathology, 2017
- EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathologyPathology - Research and Practice, 2017
- Evaluation of a fast and fully automated platform to diagnose EGFR and KRAS mutations in formalin-fixed and paraffin-embedded non-small cell lung cancer samples in less than one dayJournal of Clinical Pathology, 2017
- EGFR mutation detection on lung cancer cytological specimens by the novel fully automated PCR-based Idylla EGFR Mutation AssayJournal of Clinical Pathology, 2016
- EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancerJournal of Hematology & Oncology, 2016
- Metastatic sites and survival in lung cancerLung Cancer, 2014
- Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor ReceptorSeminars in Oncology, 2014
- Molecular biology of lung cancer.2013